Año 2022 / Volumen 114 / Número 8
Editorial
Current challenges in the functional cure of HBe-Antigen-negative chronic hepatitis B

441-444

DOI: 10.17235/reed.2022.9052/2022

Henar Calvo Sánchez, Julia Peña-Asensio, Juan Ramón Larrubia Marfil,

Resumen
This editorial discusses current challenges in treatment stop in e-antigen-negative chronic hepatitis B, with attention to immunologic and virologic markers associated with functional cure, new therapeutic options for those cases unsuitable for treatment discontinuation, and safety after treatment withdrawal.
Share Button
Nuevo comentario
Comentarios

12/09/2022 18:28:29
Parabéns, pela publicação!!


Bibliografía
1. Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology. 1999;117(6):1386-96.
2. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. The Journal of experimental medicine. 2000;191(8):1269-80.
3. Montali I, Vecchi A, Rossi M, Tiezzi C, Penna A, Reverberi V, et al. Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection. Biomedicines. 2022;10(6):1224.
4. Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? Journal of hepatology. 2022;76(6):1249-62.
5. Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nature reviews Drug discovery. 2019;18(11):827-44.
6. Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66(4):1296-313.
7. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature medicine. 1996;2(10):1104-8.
8. Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nature reviews Gastroenterology & hepatology. 2019;16(11):662-75.
9. EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology. 2017;67(2):370-98.
10. Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. Journal of hepatology. 2017;66(2):275-81.
11. Honer Zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Filmann N, Falk CS, et al. Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. The Journal of infectious diseases. 2016;214(10):1492-7.
12. Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. Journal of hepatology. 2017;67(5):918-24.
13. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012;143(3):629-36 e1.
14. Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, et al. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology. 2022;162(3):757-71 e4.
15. Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res. 2021;185:104992.
16. Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology. 2016;63(5):1481-92.
17. Moreno-Cubero E, Del Arco RTS, Pena-Asensio J, de Villalobos ES, Miquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World journal of gastroenterology. 2018;24(17):1825-38.
18. Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017;9(409).
19. Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology. 2021;73(2):843-52.
20. Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, et al. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology. 2020;72(1):42-57.
21. Gehring AJ, Mendez P, Richter K, Ertl H, Donaldson EF, Mishra P, et al. Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. Journal of hepatology. 2022.
22. Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. The Journal of clinical investigation. 2018;128(2):668-81.
23. Peña-Asensio J, Calvo H, Miquel J, Sanz-de-Villalobos E, González-Praetorius A, Torralba M, et al. Model to predict on-treatment restoration of functional HBV-specific CD8(+) cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B. Aliment Pharmacol Ther. 2022;55(12):1545-59.
24. Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther. 2022;55(7):805-19.
Artículos relacionados
Instrucciones para citar
Calvo Sánchez H, Peña-Asensio J, Larrubia Marfil J. Current challenges in the functional cure of HBe-Antigen-negative chronic hepatitis B. 9052/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1349 veces.
Este artículo ha sido descargado 189 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 03/07/2022

Aceptado: 06/07/2022

Prepublicado: 22/07/2022

Publicado: 27/07/2022

Tiempo de prepublicación: 19 días

Tiempo de edición del artículo: 24 días


Compartir
Este artículo ha sido valorado por 2 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas